Goodpasture's disease: A report of ten cases and a review of the literature

Autoimmunity Reviews

Volumn 12, Issue 11, 2013, Pages 1101-1108

  Dammacco, Franco ^a   Battaglia, Stefano ^a   Gesualdo, Loreto ^a   Racanelli, Vito ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Anti GBM antibodies; C ANCA; Glomerular basement membrane; Goodpasture's disease; Granulomatosis with polyangiitis; P ANCA

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; CANSTATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; HLA DRB1 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE;

ALLELE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; BASEMENT MEMBRANE; BRONCHOSCOPY; DIFFERENTIAL DIAGNOSIS; GLOMERULONEPHRITIS; GLOMERULUS; GOODPASTURE SYNDROME; HEMODIALYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOCHEMISTRY; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG ALVEOLUS; LUNG HEMORRHAGE; LUNG INSUFFICIENCY; MICROSCOPY; PATHOGENESIS; PLASMAPHERESIS; PROTEIN QUATERNARY STRUCTURE; REVIEW; TH1 CELL; TH2 CELL;

ANCA; ANTI-GBM ANTIBODIES; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES; C-ANCA; GBM; GD; GLOMERULAR BASEMENT MEMBRANE; GOODPASTURE'S DISEASE; GPA; GRANULOMATOSIS WITH POLYANGIITIS; P-ANCA;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; ANTIBODY SPECIFICITY; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; PLASMA EXCHANGE; YOUNG ADULT;

EID: 84881554070     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.06.014     Document Type: Review

References (71)

1. Salama A.D., Levy J.B., Lightstone L., Pusey C.D. Goodpasture's disease. Lancet 2001, 358:917-920.
2. Cui Z., Zhao M.H. Advances in human antiglomerular basement membrane disease. Nat Rev Nephrol 2011, 7:697-705. 10.1038/nrneph.2011.89.
3. Stanton M.C., Tange J.D. Goodpasture's syndrome (pulmonary haemorrhage associated with glomerulonephritis). Austral Ann Med 1958, 7:132-144.
4. Goodpasture E.W. The significance of certain pulmonary lesions in relation to the etiology of influenza. Am J Med Sci 1919, 158:863-870.
5. Scheer R.L., Grossman M.A. Immune aspects of the glomerulonephritis associated with pulmonary haemorrhage. Ann Intern Med 1964, 60:1009-1021.
6. Lerner R.A., Glassock R.J., Dixon F.J. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 1967, 126:989-1004.
7. Wilson C.B., Dixon F.J. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973, 3:74-89.
8. Cui Z., Wang H.Y., Zhao M.H. Natural autoantibodies against glomerular basement membrane exist in normal human sera. Kidney Int 2006, 69:894-899.
9. Cui Z., Zhao M.H., Segelmark M., Hellmark T. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int 2010, 78:590-597.
10. Wahls T.L., Bonsib S.M., Schuster V.L. Coexistent Wegener's granulomatosis and anti-glomerular basement membrane disease. Hum Pathol 1987, 18:202-205.
11. Phelps R.G., Rees A.J. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int 1999, 56:1638-1653.
12. Kitagawa W., Imai H., Komatsuda A., et al. The HLA-DRB1*1501 allele is prevalent among Japanese patients with anti-glomerular basement membrane antibody-mediated disease. Nephrol Dial Transplant 2008, 23:3126-3129.
13. Yang R., Cui Z., Zhao J., Zhao M.H. The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease. Clin Immunol 2009, 133:245-250.
14. Luo H., Chen M., Cui Z., et al. The association of HLA-DQB1, -DQA1 and -DPB1 alleles with anti-glomerular basement membrane (GBM) disease in Chinese patients. BMC Nephrol 2011, 12:21.
15. Segelmark M., Hellmark T. Autoimmune kidney diseases. Autoimmun Rev 2010, 9:A366-A371.
16. Lahmer T., Heemann U. Anti-glomerular basement membrane antibody disease: a rare autoimmune disorder affecting the kidney and the lung. Autoimmun Rev 2012, 12:169-173.
17. Cui Z., Zhao M.H., Singh A.K., Wang H.Y. Antiglomerular basement membrane disease with normal renal function. Kidney Int 2007, 72:1403-1408.
18. Basford A.W., Lewis J., Dwyer J.P., Fogo A.B. Membranous nephropathy with crescents. J Am Soc Nephrol 2011, 22:1804-1808.
19. Zhao J., Yan Y., Cui Z., et al. The immunoglobulin G subclass distribution of anti-GBM autoantibodies against α3(IV)NC1 is associated with disease severity. Hum Immunol 2008, 70:425-429.
20. Levy J.B., Hammad T., Coulthart A., Dougan T., Pusey C.D. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004, 66:1535-1540.
21. Serratrice J., Chiche L., Dussol B., et al. Sequential development of perinuclear ANCA-associated vasculitis and anti-glomerular basement membrane. Am J Kidney Dis 2004, 43:26-30.
22. Mulpuru S., Touchie C., Karpinski J., Humphrey-Murto S. Coexistent Wegener's granulomatosis and Goodpasture's disease. J Rheumatol 2010, 37:1786-1787.
23. Shin J., Park S.J., Kim J.H. Coexistent Wegener's granulomatosis and Goodpasture's disease: what Is the mechanism?. J Rheumatol 2011, 38:1521.
24. DE Zoysa J., Taylor D., Thein H., Yehia M. Incidence and features of dual anti-GBM-positive and ANCA-positive patients. Nephrology (Carlton) 2011, 16:725-729.
25. Saus J., Wieslanderll J., Langeveldll J.P.M., Quinones S., Hudson B.G. Identification of the Goodpasture antigen as the a3(IV) chain of collagen IV. J Biol Chem 1988, 15:13374-13380.
26. Netzer K.O., Leinonen A., Boutaud A., et al. The Goodpasture autoantigen. Mapping the major conformational epitope(s) of alpha3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain. J Biol Chem 1999, 274:11267-11274.
27. Hellmark T., Burkhardt H., Wieslander J. Goodpasture disease. Characterization of a single conformational epitope as the target of pathogenic autoantibodies. J Biol Chem 1999, 274:25862-25868.
28. Sundaramoorthy M., Meiyappan M., Todd P., Hudson B.G. Crystal structure of NC1 domains. Structural basis for type IV collagen assembly in basement membranes. J Biol Chem 2002, 277:31142-31153.
29. Than M.E., Henrich S., Huber R., et al. The 1.9-A crystal structure of the non-collagenous (NC1) domain of human placenta collagen IV shows stabilization via a novel type of covalent Met-Lys cross-link. Proc Natl Acad Sci U S A 2002, 99:6607-6612.
30. Pedchenko V., Vanacore R., Hudson B. Goodpasture's disease: molecular architecture of the autoantigen provides clues to etiology and pathogenesis. Curr Opin Nephrol Hypertens 2011, 20:290-296.
31. Borza D.B., Bondar O., Colon S., et al. Goodpasture autoantibodies unmask cryptic epitopes by selectively dissociating autoantigen complexes lacking structural reinforcement: novel mechanisms for immune privilege and autoimmune pathogenesis. J Biol Chem 2005, 280:27147-27154.
32. McCoy R.C., Johnson H.K., Stone W.J., Wilson C.B. Absence of nephritogenic GBM antigen(s) in some patients with hereditary nephritis. Kidney Int 1982, 21:642-652.
33. Hudson B.G., Kalluri R., Gunwar S., et al. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the α3(IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int 1992, 42:179-187.
34. Hudson B.G., Tryggvason K., Sundaramoorthy M., Neilson E.G. Alport's syndrome, Goodpasture's syndrome, and Type IV collagen. N Engl J Med 2003, 348:2543-2556.
35. Kruegel J., Rubel D., Gross O. Alport syndrome-insights from basic and clinical research. Nat Rev Nephrol 2013, 9:170-178.
36. Pedchenko V., Bondar O., Fogo A.B., et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 2010, 363:343-354.
37. Sheerin N.S., Springall T., Carroll M.C., Hartley B., Sacks S.H. Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 1997, 110:403-409.
38. Trouw L.A., Seelen M.A., Daha M.R. Complement and renal disease. Mol Immunol 2003, 40:125-134.
39. Fujii T., Hamano Y., Ueda S., et al. Predominant role of FcgammaRIII in the induction of accelerated nephrotoxic glomerulonephritis. Kidney Int 2003, 64:1406-1416.
40. Giorgini A., Brown H.J., Lock H.R., et al. FcγRIII and FcγRIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J Immunol 2008, 181:8745-8752.
41. Otten M.A., Groeneveld T.W., Flierman R., et al. Both complement and IgG Fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice. J Immunol 2009, 183:3980-3988.
42. Duffield J.S., Tipping P.G., Kipari T., et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol 2005, 167:1207-1219.
43. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
44. Ricardo S.D., van Goor H., Eddy A.A. Macrophage diversity in renal injury and repair. J Clin Invest 2008, 118:3522-3530.
45. Aki K., Shimizu A., Masuda Y., et al. ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol 2010, 298:F870-F882.
46. Han Y., Ma F.Y., Tesch G.H., Manthey C.L., Nikolic-Paterson D. c-fms blockade reverses glomerular macrophage infiltration and halts development of crescentic anti-GBM glomerulonephritis in the rat. Lab Invest 2011, 91:978-991.
47. Kitching A.R., Turner A.L., Semple T., et al. Experimental autoimmune anti-glomerular basement membrane glomerulonephritis: a protective role for IFN-gamma. J Am Soc Nephrol 2004, 15:1764-1774.
48. Chen L., Hellmark T., Pedchenko V., et al. A nephritogenic peptide induces intermolecular epitope spreading on collagen IV in experimental autoimmune glomerulonephritis. J Am Soc Nephrol 2006, 17:3076-3081.
49. Reynolds J., Sallie B.A., Syrganis C., Pusey C.D. The role of T-helper lymphocytes in priming for experimental autoimmune glomerulonephritis in the BN rat. J Autoimmun 1993, 6:571-585.
50. Zou J., Hannier S., Cairns L.S., et al. Healthy individuals have Goodpasture autoantigen-reactive T cells. J Am Soc Nephrol 2008, 19:396-404.
51. Ooi J.D., Holdsworth S.R., Kitching A.R. Advances in the pathogenesis of Goodpasture's disease: from epitopes to autoantibodies to effector T cells. J Autoimmun 2008, 31:295-300.
52. Cairns L.S., Phelps R.G., Bowie L., et al. The fine specificity and cytokine profile of T-helper cells responsive to the alpha3 chain of type IV collagen in Goodpasture's disease. J Am Soc Nephrol 2003, 14:2801-2812.
53. Afzali B., Lombardi G., Lechler R.I., Lord G.M. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007, 148:32-46.
54. Timoshanko J., Holdsworth S., Kitching A., Tipping P. IFN-gamma production by intrinsic renal cells and bone-marrow derived cells is required for full expression of crescentic glomerulonephritis in mice. J Immunol 2002, 168:4135-4141.
55. Mesnard L., Keller A.C., Michel M.L., et al. Invariant natural killer T cells and TGF-beta attenuate anti-GBM glomerulonephritis. J Am Soc Nephrol 2009, 20:1282-1292.
56. Huang X.R., Tipping P.G., Shuo L., Holdsworth S.R. Th1 responsiveness to nephritogenic antigens determines susceptibility to crescentic glomerulonephritis in mice. Kidney Int 1997, 51:94-103.
57. Kitching A.R., Holdsworth S.R., Tipping P.G. Crescentic glomerulonephritis, a manifestation of a nephritogenic Th1 response?. Histol Histopathol 2000, 15:993-1003.
58. Kapler J., Roehm M., Marrack P. T cell tolerance by clonal deletion in the thymus. Cell 1987, 49:273-280.
59. Robertson J., Wu J., Arends J., et al. Spontaneous recovery from early glomerular inflammation is associated with resistance to anti-GBM glomerulonephritis: tolerance and autoimmune tissue injury. J Autoimmun 2008, 30:246-256.
60. Zou J., Henderson L., Thomas V., Swan P., Turner A.N., Phelps R.G. Presentation of the Goodpasture autoantigen requires proteolytic unlocking steps that destroy prominent T cell epitopes. J Am Soc Nephrol 2007, 18:771-779.
61. Gan P.Y., Steinmetz O.M., Tan D.S., et al. Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol 2010, 21:925-931.
62. Nogueira E., Hamour S., Sawant D., et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2010, 25:2209-2217.
63. Yang R., Hellmark T., Zhao J., et al. Levels of epitope-specific autoantibodies correlate with renal damage in anti-GBM disease. Nephrol Dial Transplant 2009, 24:1838-1844.
64. Syeda U.A., Singer N.G., Magrey M. Anti-glomerular basement membrane antibody disease treated with rituximab: a case based review. Semin Arthritis Rheum 2013, 42:567-572.
65. Peto P., Salama A.D. Update on antiglomerular basement membrane disease. Curr Opin Rheumatol 2011, 23:32-37.
66. García-Cantón C., Toledo A., Palomar R., et al. Goodpasture's syndrome treated with mycophenolate mofetil. Nephrol Dial Transplant 2000, 15:920-922.
67. Szczepiorkowski Z.M., Bandarenko N., Kim H.C. Guidelines on the use of therapeutic apheresis in clinical practice: evidence based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007, 22:106-175.
68. Pusey C.D., Levy J.B. Plasmapheresis in immunologic renal disease. Blood Purif 2012, 33:190-198.
69. Lockwood C.M., Rees A.J., Pearson T.A., et al. Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet 1976, 1(7962):711-715.
70. Levy J.B., Turner A.N., Rees A.J., Pusey C.D. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001, 134:1033-1042.
71. Remuzzi G., Perico N., Macia M., Ruggenenti P. The role of renin angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int 2005, (Suppl. 68):S57-S65.